Title: Finding Synergies for the 3Rs – Repeated Dose Toxicity Testing: Report from an EPAA Partners' Forum
Authors: LAROCHE CHARLESANNYS ERWINBENDER HANSBOTELHO DANIELLEBOTHAM PHILBRENDLER SCHWAAB SUSANNECLAYTON RICKCORVARO MARCODAL NEGRO GIANNIDELANNOIS FRÉDÉRIQUEDENT MATTHEWDESAINTES CHRISTIANDESPREZ BERTRANDDHALLUIN STEPHANEHARTMANN ANDREASHOFFMANN-DOERR SIMONEHUBESCH BRUNOIRIZAR AMAIAMANOU IRENEMULLER BORIS P.NADZIALEK STEPHANIEPRIETO PERAITA MARIA DEL PILARRASENBERG MIKEROGGEBAND ROBROWAN TIM GSCHUTTE KATRINVAN DE WATER BOBWESTMORELAND CARLWHELAN MAURICEWILSCHUT ANNETTEZVONIMIR ZVONARCRONIN MARK
Citation: REGULATORY TOXICOLOGY AND PHARMACOLOGY vol. 108 p. 104470
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE
Publication Year: 2019
JRC N°: JRC115973
ISSN: 0273-2300 (online)
URI: https://doi.org/10.1016/j.yrtph.2019.104470
http://publications.jrc.ec.europa.eu/repository/handle/JRC115973
DOI: 10.1016/j.yrtph.2019.104470
Type: Articles in periodicals and books
Abstract: The European Partnership for Alternative Approaches to Animal Testing (EPAA) convened a Partners' Forum on repeated dose toxicity (RDT) testing to identify synergies between industrial sectors and stakeholders along with opportunities to progress these in existing research frameworks. Although RTD testing is not performed across all industrial sectors, the OECD accepted tests can provide a rich source of information and play a pivotal role for safety decisions relating to the use of chemicals. Currently there are no validated alternatives to repeated dose testing and a direct one-to-one replacement is not appropriate. However, there are many projects and initiatives at the international level which aim to implement various aspects of replacement, reduction and refinement (the 3Rs) in RDT testing. Improved definition of use, through better problem formulation, aligned to harmonisation of regulations is a key area, as is the more rapid implementation of alternatives into the legislative framework. Existing test designs can be optimised to reduce animal use and increase information content. Greater use of exposure-led decisions and improvements in dose selection will be beneficial. In addition, EPAA facilitates sharing of case studies demonstrating the use of Next Generation Risk Assessment applying various New Approach Methodologies to assess RDT.
JRC Directorate:Health, Consumers and Reference Materials

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.